Form 8-K - Current report:
SEC Accession No. 0001193125-26-104102
Filing Date
2026-03-12
Accepted
2026-03-12 16:05:29
Documents
12
Period of Report
2026-03-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bolt-20260312.htm   iXBRL 8-K 47179
2 EX-99.1 bolt-ex99_1.htm EX-99.1 372219
3 GRAPHIC img192637872_0.gif GRAPHIC 3668
  Complete submission text file 0001193125-26-104102.txt   552304

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT bolt-20260312.xsd EX-101.SCH 25969
15 EXTRACTED XBRL INSTANCE DOCUMENT bolt-20260312_htm.xml XML 4938
Mailing Address 900 CHESAPEAKE DRIVE REDWOOD CITY CA 94063
Business Address 900 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 650-665-9295
Bolt Biotherapeutics, Inc. (Filer) CIK: 0001641281 (see all company filings)

EIN.: 472804636 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39988 | Film No.: 26747622
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)